


PHARMACEUTICAL 2019

Strongbridge Biopharma plc Rank 17 of 371





PHARMACEUTICAL 2019



Strongbridge Biopharma plc Rank 17 of 371

The relative strengths and weaknesses of Strongbridge Biopharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Strongbridge Biopharma plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 531% points. The greatest weakness of Strongbridge Biopharma plc is the variable Revenues, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 554% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	132,298
Cost of Goods Sold	0
Intangible Assets	37,388
Liabilities, Current	17,249
Liabilities, Non-Current	0
Other Assets	305
Other Compr. Net Income	0
Other Expenses	11,709
Other Liabilities	40,081
Other Net Income	114,310
Property and Equipment	294
Research and Development	25,441
Revenues	18,027
Selling, General and Administrative Expense	63,336

Output Variable	Value in 1000 USD
Assets	170,285
Liabilities	57,330
Expenses	100,486
Stockholders Equity	112,955
Net Income	31,851
Comprehensive Net Income	31,851
Economic Capital Ratio	223%